Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
No patent data available. Pre-approval drugs may not have Orange Book listings.
Teduglutide Viatris
Teduglutide Viatris is indicated for the treatment of patients 4 months corrected gestational age and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.
View on EMARevestive
Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery. Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome. Patients should be stable following a period of intestinal adaptation after surgery.
View on EMAFabry Disease
Type 2 Diabetes Mellitus
Primary Immunodeficiency Diseases (PID)
Primary Immunodeficiency Disease
Hypertension